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Results: Both liver tissue and serum were tested for 6 cases, serum only for 8 cases, and liver only for 4 cases. Twelve horses received tetanus antitoxin (TAT) 4-12.7 weeks (median = 8 weeks), 3 horses received commercial equine plasma 6-8.6 weeks, and 3 horses received allogenic stem cells 6.4-7.6 weeks before the onset of hepatic failure. All samples were TDAV negative. Two of 14 serum samples were NPHV-positive. Six of 14 serum samples were EPgV-positive. All liver samples were NPHV-negative and EPgV-negative. EqPV-H was detected in the serum (N = 8), liver (N = 4), or both samples (N = 6) of all 18 cases. The TAT of the same lot number was available for virologic testing in 10 of 12 TAT-associated cases, and all 10 samples were EqPV-H positive.
Conclusions and Clinical Importance:
We demonstrated EqPV-H in 18 consecutive cases of serum hepatitis. EPgV, TDAV, and NPHV were not consistently present. This information should encourage blood product manufacturers to test for EqPV-H and eliminate EqPV-H-infected horses from their donor herds.
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| INTRODUCTION
Equine serum hepatitis, also known as Theiler's disease or idiopathic acute hepatitis, is a serious and often life-threatening disease of adult horses that was 1st described in 1918 in South Africa by Sir Arnold
Theiler. 1 The 1st cases of serum hepatitis in horses reported in the United States occurred during the pandemic of western equine encephalomyelitis in the 1930s. [2] [3] [4] [5] The incidence of fulminant hepatitis among horses receiving antiserum in these outbreaks was between 1.4% and 18%. 1, 4 Serum hepatitis has since been described in horses worldwide after treatment with a variety of equine serum products, including tetanus antitoxin (TAT), [6] [7] [8] [9] [10] [11] [12] botulinum antitoxin, 13 Streptococcus equi antiserum, 7,14 pregnant mare's serum, 7 and equine plasma. 15 Of these equine biologic products, the disease has been most commonly associated with TAT, possibly because this is the most frequently administered equine blood origin biologic product. [6] [7] [8] [9] [10] [11] [12] The incubation period for clinical disease usually ranges between 4 and 10 weeks after administration of an equine origin biologic, although it can be as long as 14 weeks. 1, 4, 8 In the majority of cases, the association of equine serum hepatitis with the parenteral injection of antiserum or plasma suggests an infectious blood-borne cause, and the history, incubation period, and histopathologic findings appear most similar to serum hepatitis (hepatitis B) in human beings. 14 Recently, 3 novel flaviviruses were identified in horses, of which 2, non-primate hepacivirus (NPHV) and Theiler's disease-associated virus (TDAV) were proposed to be associated with liver disease. 13, 16, 17 NPHV, also called equine hepacivirus, is a member of the genus Hepacivirus, 16, 18 and its hepatotropism and production of hepatic disease after experimental and natural infection in horses is well documented. [19] [20] [21] [22] [23] [24] [25] TDAV is a member of the genus Pegivirus and was identified during an outbreak of acute clinical hepatitis in horses, 6 weeks after prophylactic administration of botulinum antitoxin of equine origin. 13 TDAV's close relative, equine pegivirus (EPgV), commonly infects horses in the United States, Western Europe, and China, although this virus is not hepatotropic and has not been associated with hepatic disease. 17, 26, 27 NPHV and EPgV are frequently detected in commercial horse serum pools, whereas TDAV is not.
28,29
More recently, a novel equine parvovirus (equine parvovirus-hepatitis, EqPV-H) was discovered in the liver and serum of a horse that died of
Theiler's disease. 30 EqPV-H nucleic acids were also found in the TAT administered to this horse 9 weeks before onset of hepatitis. Experimental administration of EqPV-H-positive TAT samples to 2 horses resulted in EqPV-H viremia 6.4 weeks later, followed by marked bio- 
| Statistics
Descriptive statistics of demographic data are provided. Continuous variables are reported as median and range because of non-Gaussian distribution of some variables, as assessed by the examination of skewness, kurtosis, and Q-Q plots.
3 | RESULTS
| Signalment and biologic product history
Eighteen cases of serum hepatitis were enrolled between December 2014 and February 2018. Demographic data and virologic testing are summarized in Table 2 , and greater individual case details are included in Supporting Information Supplemental Table 1 . Multiple breeds of horses were affected. There were 6 mares, 1 stallion, and 11 geldings. The ages ranged from 2 to 18 (median 12) years. Of the 18 cases, 12 horses received commercial TAT 4-13 weeks (median 8 weeks) before acute onset of signs of liver failure. The antitoxin (same vial or lot number) was available for testing in 11 cases. In 4 cases, the TAT lot number was narrowed to 2 possibilities and both were tested (Supporting Information Supplemental Table 1 ). In 2 of these cases, PCR results were the same for both lots. In the other 2 cases, there was a discrepancy between the 2 lots in either NPHV 
| Virology
All 18 horses were positive for EqPV-H infection (Table 2 ). Serum and liver samples were available for testing in 6 of the 18 cases; serum only was available in 8 cases and liver only in 4 cases; all these samples were positive for EqPV-H. Of the 14 serum samples, 5 were also positive for EPgV, 2 were positive for NPHV, but none of the 14 samples were positive for TDAV. All 10 liver samples were only positive for EqPV-H. Twelve of the 18 horses died (n = 6) or were euthanized (n = 6) because of the severity of liver failure. One of the horses (case 7) that survived acute fulminant hepatitis was tested 13 months later and still had detectable
EqPV-H viremia without any biochemical evidence of hepatic disease.
| In-contact horses
The newborn foal of case 4 received the same TAT as her dam at foaling. Serum from the foal was also EqPV-H positive (viremia was 100-fold higher than the dam) when tested at 8 weeks of age; the foal was clinically normal; however, no biochemical analysis was performed. After case 5 recovered and returned to the farm, an in-contact horse developed clinical and biochemical findings of liver failure 6 weeks later. This horse was also sent to the university (Missouri) referral hospital, diagnosed with acute hepatic failure, successfully treated, and returned to the farm 1 week later. The serum of this in-contact horse also tested positive for EqPV-H but no biologic product had been administered to this horse, suggesting the possibility of horse-to-horse transmission (from case 5) as has sporadically been observed in serum hepatitis outbreaks. 1, 11 In case 6, the field veterinarian reported that 2 horses had been inoculated with the same lot of TAT after castration and both developed signs of liver failure, although only 1 of the horses (case 6) was referred for hospitalization and included in our study. Case 6 died, although the other horse recovered on the farm and a blood sample from that horse was positive for EqPV-H.
| Clinical data
Although not a primary aim of the study, information on clinical signs, were reported as having predominantly cerebral signs, including blindness, head pressing, and obtundation, whereas 2 horses had acute ataxia that preceded the cortical signs. Other initial clinical findings noted in the case records that were provided included icterus (n = 9), discolored urine (n = 5), colic signs with gastric reflux (n = 2), and recumbency in 1 horse that was severely hypoglycemic. Pyrexia was only reported in 2 cases. In 7 cases, the owners reported decreased appetite and dullness for 1-2 days before the onset of neurologic signs. Serum biochemistry findings at referral admission are summarized in Table 3 . Median percentage direct to total bilirubin was 17% (13%-27%, n = 7). Glucose values were reported for 9 horses. Two values were moderately low (60 and 52 mg/dL), and 2 values were severely low (<20 mg/dL) in recumbent horses. Duration of clinical signs before death or euthanasia (median 3 days, range 1-7 days) was available in all 12 horses that died. Information regarding time to clinical improvement after hospitalization was available for 4 of 5 surviving horses, and number of days after hospitalization to clinical improvement was 3, 3, 4, and 7 days. One horse (case 16) was being treated for a chronic respiratory disease and had a complete blood chemistry panel (which was normal) 8 days before onset of liver failure. This was the only horse in the study receiving medical treatment for another condition at the time of onset of liver failure.
Gross findings of the liver were noted on 7 of the necropsy reports, and in all but 1, the liver was reported to be small (normal 
| DISCUSSION
The 18 cases in our study were (1) clinically and clinicopathologically consistent with previous descriptions of serum hepatitis in horses, (2) all infected with EqPV-H, and (3) rarely infected with the equine flaviviruses that have recently been suspected of causing the disease. 13, 19 When samples of the biologic product or their same lot number were available for virus testing, EqPV-H was found in the products administered to the horses before onset of hepatitis. Despite the limitation of a lack of controls, the 100% EqPV-H prevalence among these 18 cases compared to the low prevalence of 13% EqPV-H viremia among normal horses 30 is highly suggestive that this association is significant. These findings are indicative that EqPV-H can be transmitted by administration of equine biologic products and is the likely cause of equine serum hepatitis.
The clinical and histopathologic findings in these cases, along with the knowledge of administration of an equine origin blood product 4-12 weeks earlier, were considered diagnostic for serum hepatitis; [6] [7] [8] [9] 11, 12, 15 therefore, additional testing (eg, heavy metals and other hepatotoxins) was limited. All except 1 horse in our study were in the "typical" 4-to 10-week incubation period for serum hepatitis, 8, [10] [11] [12] 15 and the longest incubation period was 12.7 weeks. The association of equine plasma administration and serum hepatitis is also well documented. The time between plasma administration and development of hepatic failure in the 3 cases in our study is typical of previous plasma-associated cases of serum hepatitis. 13, 15 The 2 plasma products (2 horses received the same lot number) administered to these horses were not available for virus testing; therefore, the spread of infection by commercial plasma in these 3 plasmarelated cases remains presumed.
An association between the allogenic stem cell treatment and serum hepatitis, as occurred in 3 horses in our study, has not been previously reported. The incubation period between the stem cell inoculation and the onset of disease in these 3 horses was typical for serum hepatitis. In only 1 horse (case 17) was the stem cell inoculum available for testing, and although this sample was EqPV-H positive, TDAV was discovered 13 showed that EqPV-H was also present in the antitoxin, in diseased horses on the farm, and in the 4 experimental horses inoculated with the same plasma antitoxin lot. 30 Parvovirus was likely not detected in the original investigation because sequencing in that study focused on RNA viruses with proximity to hepatitis C virus, and so a DNAase treatment was performed on the RNA pellet before sequencing. 13 Although TDAV and EPgV nucleic acids have been found in commercial plasma and serum products, 13, 29 pegiviruses are neither believed to be hepatotropic nor have they been documented to cause liver disease in any mammalian species. 17, 26, 37 Our findings also suggests that they are rarely transmitted via TAT administration.
Epidemiologic data regarding Theiler's disease and virologic testing for EqPV-H are both consistent with the theory that subclinical or silent infection is likely common. This is supported by the low incidence of clinical disease after inoculation with the same biologic product. 1, 4, 11, 13 In addition, subclinical disease has been documented in multiple horses in 2 studies of biologic-associated serum hepatitis outbreaks, 11, 13 and in one of these outbreaks, disease was demonstrated to be associated with EqPV-H. 13, 30 Similarly, 2 horses experimentally inoculated with EqPV-H developed only mild clinical or subclinical disease. 30 Finally, a seroprevelance survey of 100 horses found that 13% of horses without biochemical evidence of liver disease were EqPV-H positive, 30 suggesting that most horses that become infected with EqPV-H do not develop clinical disease. Taken together, these findings suggest that many horses infected with
EqPV-H could have a short period of subclinical disease followed by complete recovery. Why some horses develop severe and often fatal disease after EqPV-H infection and others do not is unknown. Hepatic cell damage related to the high level of viremia and direct cytopathic effects is one possibility. Alternatively, injury might result as an indirect consequence of the immune response directed against the virus or injured hepatocytes, as occurs with hepatitis B virus in people.
